Integrating Portal Hypertension and HCC into a Unified Stage-Based Cirrhosis Model : Nat Rev Gastroenterol Hepatol | May 2026

Introduction

Cirrhosis and hepatocellular carcinoma (HCC) represent closely interconnected consequences of chronic liver disease, with portal hypertension serving as a central driver of hepatic decompensation and a major determinant of prognosis. Despite this biologic overlap, clinical management frameworks have traditionally approached portal hypertension and HCC as separate entities.

Problem Statement

Current guidelines frequently fail to integrate cirrhosis stage, clinically significant portal hypertension (CSPH) and HCC stage into a unified prognostic model. This separation may lead to suboptimal treatment selection, inaccurate risk stratification and inadequate personalization of therapy, particularly when determining candidacy for curative interventions such as hepatic resection or transplantation.

Summary

This review proposes a clinically integrated, stage-based framework that combines cirrhosis severity, portal hypertension status and HCC stage to guide prognostication and therapeutic decision-making. The authors emphasize that CSPH represents a critical biologic and clinical milestone in compensated cirrhosis, strongly influencing risk of decompensation, survival and eligibility for curative HCC therapies. Importantly, the review highlights the transition from invasive hepatic venous pressure gradient measurement toward non-invasive assessment using liver stiffness and platelet-based tools, with emerging evidence suggesting these methods may soon become standard even in patients with HCC. The article further argues that management strategies should differ substantially according to the interaction between cirrhosis stage and tumor burden rather than relying on tumor stage alone. In compensated cirrhosis without CSPH, aggressive curative approaches may remain feasible, whereas decompensated disease substantially limits therapeutic tolerance and prognosis independent of tumor stage. The authors also call for future HCC clinical trials to incorporate cirrhosis stage and portal hypertension stratification into study design and outcome analysis. Overall, this review advances an important conceptual shift toward fully integrated hepatology-oncology care, where liver function, portal hypertension and tumor biology are evaluated simultaneously to optimize individualized management in cirrhosis-associated HCC.